CADMATIC
12.1.2023 06:01:40 CET | Business Wire | Press release
Cadmatic is part of a consortium of industrial companies and academic institutions that is leading the EU-funded Smart European Shipbuilding project (SEUS) that was launched 1 January 2023. SEUS is an EU Innovation Action with a focus on computational tools for shipbuilding. The consortium will create a framework for data-driven shipbuilding by developing a new integrated platform that incorporates early and detailed ship design solutions, data management, and collaboration software.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005065/en/
Cadmatic is Part of Consortium Leading EU-Funded SEUS Project for Smarter and More Productive Shipbuilding (Photo: Business Wire)
The platform solution aims to slash the time needed for ship engineering by 30% and cut assembly times by an ambitious 20%. It will be built with the best EU shipbuilding expertise provided by the academic and industrial consortium participants and evaluated at two leading European shipyards.
The platform solution will develop novel practices for human-centric knowledge management, data-driven AI design elements, intelligent technology, and an Industry 5.0 concept for shipbuilding. It will also support the growth of a European workforce that is highly skilled in the deployment and use of advanced computational tools in shipbuilding, particularly with respect to the integration of new technologies.
SEUS is part of Horizon Europe, the EU’s flagship research and innovation program with a budget of €95,5 billion. SEUS is funded to the tune of approximately €7 million, of which Cadmatic will receive €1,6 million. Cadmatic is responsible for leading the technical coordination of the four-year-long SEUS project.
The SEUS consortium consists of 8 organizations from 5 countries. The members include highly innovative partners such as well-established shipbuilding solution provider Cadmatic (Finland), PLM data management solution developer Contact Software (Germany), SARC BV (The Netherlands), two shipyards with different profiles in Ulstein Group (Norway) and Astilleros Gondan SA (Spain), and outstanding research institutes: the Norwegian University of Science and Technology (Norway), Turku University (Finland), and NHL Stenden University of Applied Sciences (The Netherlands).
“We are proud to be leading the technical coordination and working alongside the other consortium partners on this ambitious project. It is very exciting to use our shipbuilding expertise to incorporate CAE/CAD/CAM and PLM elements in a single innovative and groundbreaking platform that will take shipbuilding efficiency to the next level,” says Ludmila Seppälä, Business Development Director at Cadmatic.
About Cadmatic
Cadmatic is a leading developer of digital and intelligent 3D design and information management software solutions for the marine, power, process, and construction industries. It empowers engineers to build a brighter future and a better world by making the design, engineering, construction and operation of ships, industrial plants and buildings better, faster and easier. Cadmatic has over 6000 customer organizations in 60 countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005065/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies23.6.2026 15:30:00 CEST | Press release
Saturnus Bio is a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet needThe collaboration will augment Merck’s efforts to pursue precision medicine-defined indicationsNot intended for Canada-, UK- or US-based media Merck, a leading global science and technology company, today announced a strategic research-stage collaboration with Saturnus Bio, a Versant Ventures-founded biotech, aimed at establishing a foundational portfolio in the promising field of rare genetic cardiomyopathies. This partnership aligns with the company’s commitment to address significant unmet medical needs in rare populations through targeted treatments. “Through our partnership with Saturnus Bio, we aim to fast track the development of innovative therapies for genetic cardiomyopathies through precision cardiology, targeting the rare population impacted by these conditions,” said David Weinreich, MD, Head of Resea
Beyond the ‘Dumb Pipe’: How Agentic AI and Sovereign Networks Are Redefining Connectivity23.6.2026 14:46:00 CEST | Press release
The global connectivity market is shifting. With traditional European telecom growth slowing to 2-3% by 2029, businesses must adapt through Agentic AI, critical communications, and digital sovereignty. To remain competitive, operators should move beyond infrastructure toward an API-driven economy. These trends took center stage at Comarch User Group 2026. The conference hosted over 700 partners from 53 countries, including 201 connectivity experts, highlighting how companies can thrive in regulated environments. As telecom growth slows, demand for broader connectivity solutions across satellite, logistics, and critical communications is surging. Operators must abandon the old 4G “dumb pipe” model, where they act merely as network providers charging only for raw data transmission, for an API-driven economy with programmable network quality, securely integrating 5G with new satellite and IoT ecosystems. - Marcin Kaleta, CEO at Comarch Communications Putting Agentic AI in the Driver's Sea
Mary Kay Extends Winning Streak With Fourth Year as #1 in Global Direct Selling Beauty23.6.2026 14:03:00 CEST | Press release
Euromonitor International Recognizes Mary Kay’s Sustained Leadership In Skin Care And Color Cosmetics Mary Kay Inc., the iconic beauty and entrepreneurship company, has once again been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World1 by Euromonitor International, sustaining its legacy of excellence for the fourth consecutive year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623487381/en/ Mary Kay Inc., the iconic beauty and entrepreneurship company, for the fourth year in a row has been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World by Euromonitor International. (Image Credit: Mary Kay Inc.) “Earning the #1 global ranking from Euromonitor for the fourth consecutive year comes as a powerful endorsement of the impact of our Independent Beauty Consultants around the world who drive our success every day,” said Ryan Rogers, Chief Executive Officer of Mary Kay
Kobie 2026 Heart of Loyalty Report Reveals Growing Gap Between Consumer Expectations and Brand Loyalty Strategies23.6.2026 14:00:00 CEST | Press release
Global study finds consumers are more ready for AI, more willing to share data, and more motivated by recognition and shared values than many brands realize Kobie, a global leader in loyalty technology and services, today released its 2026 Heart of Loyalty Report, which surveyed both consumers and practitioners, revealing significant gaps between consumer expectations and brand loyalty strategies across AI adoption, data sharing, recognition, advocacy, and community engagement. Kobie's 2026 Heart of Loyalty Report found that: 57% of consumers are willing to engage with AI-powered brand experiences, yet 56% of loyalty practitioners believe customers are not ready for AI. 77% of consumers want recognition from brands, but only 55% feel seen as individuals. 72% of consumers say they would refer a brand without an incentive, yet many referral strategies remain heavily dependent on rewards. Rewards are the strongest driver of willingness to share personal data, yet only 65% of practitioners
Veristat Strengthens Biostatistics, Drug Development Advisory, and People Leadership to Support Growth in Complex Clinical Development23.6.2026 13:05:00 CEST | Press release
Dr. Zhaohui Su and Dr. Gil Fine deepen Veristat’s biostatistics expertise, Scott Tarrant leads Strategic Drug Development Advisory, and Clint Wolfe joins as Chief Human Resources Officer VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, today announced four strategic leadership hires that advance its mission to accelerate novel therapy approvals in complex disease areas, including cell and gene therapy, oncology, and rare disease. Building on its 30-year foundation in biostatistics and its recent acquisition of the medical writing and regulatory submission business of Certara, Veristat is deepening its scientific expertise and expanding its operational leadership to meet growing client demand. Dr. Zhaohui Su and Dr. Gil Fine join Veristat’s Strategic Drug Development Advisory team in biostatistical leadership roles, collaborating with Scott Tarrant, who has been named Executive Vice President of the team. In addition, Clint Wolfe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom